Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

Autor: Kazimierz Kuliczkowski, Jean Roy, Vernon Louw, Douwe H. Biesma, Eberhard Gunsilius, Corinne Haioun, Roman Hajek, Robert Orlowski, JESUS SAN MIGUEL, Mathilde Hunault, Adrian Alegre Amor
Přispěvatelé: Hematology
Rok vydání: 2008
Předmět:
Male
Cancer Research
Combination therapy
medicine.medical_treatment
Salvage therapy
Pharmacology
Polyethylene Glycols
Bortezomib
03 medical and health sciences
0302 clinical medicine
Immune Regulation [NCMLS 2]
immune system diseases
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
cardiovascular diseases
bortezomib
lenalidomide
multiple myeloma
pegylated liposomal doxorubicin
recurrent
refractory
thalidomide
Lenalidomide
neoplasms
Multiple myeloma
Molecular diagnosis
prognosis and monitoring [UMCN 1.2]
Salvage Therapy
Chemotherapy
business.industry
Immunotherapy
gene therapy and transplantation [UMCN 1.4]
Middle Aged
medicine.disease
Boronic Acids
Thalidomide
3. Good health
Survival Rate
Oncology
Doxorubicin
Pyrazines
030220 oncology & carcinogenesis
Disease Progression
Proteasome inhibitor
Female
lipids (amino acids
peptides
and proteins)
Neoplasm Recurrence
Local
Multiple Myeloma
business
030215 immunology
medicine.drug
Zdroj: Cancer, 112, 1529-37
Cancer, 112, 7, pp. 1529-37
Cancer, 112(7), 1529-1537. John Wiley & Sons Inc.
ISSN: 1097-0142
0008-543X
DOI: 10.1002/cncr.23326
Popis: Item does not contain fulltext BACKGROUND: Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). In the current analysis, they determined 1) the efficacy of PLD plus bortezomib versus bortezomib alone in patients with MM who had failed on prior thalidomide/lenalidomide (immunomodulatory drug [IMiD]) treatment and 2) the efficacy and safety profile of PLD plus bortezomib in IMiD-exposed and IMiD-naive patients. METHODS: This prespecified analysis included 646 patients who were randomized to receive either PLD with bortezomib (n=324; 194 IMiD-naive patients and 130 IMiD-exposed patients) or bortezomib alone (n=322; 184 IMiD-naive patients and 138 IMiD-exposed patients). The primary efficacy endpoint was TTP, and secondary endpoints included overall survival, response rate, and safety. RESULTS: The median TTP was significantly longer with PLD plus bortezomib compared with bortezomib alone in IMiD-exposed patients (270 days vs 205 days). No statistical difference was noted with respect to TTP between IMiD-naive (295 days) versus IMiD-exposed (270 days) subgroups who received PLD plus bortezomib. A sustained trend favoring combination therapy was observed in analyses of overall survival. In patients who achieved a response, the response duration was comparable for IMiD-naive patients and IMiD-exposed patients in the combination treatment group and lasted a median of 310 days and 319 days, respectively. The incidence of grade 3/4 adverse events was similar with PLD plus bortezomib regardless of prior IMiD exposure. CONCLUSIONS: A significantly prolonged TTP was observed with combined PLD plus bortezomib combination therapy compared with bortezomib alone despite prior IMiD exposure. For the combination treatment arm in the IMiD-naive and IMiD-exposed subgroups, TTP was comparable. Similarly, the safety profile of the PLD plus bortezomib combination was unaltered by prior IMiD exposure.
Databáze: OpenAIRE
Externí odkaz: